Revenue: As of FY2025 Q3, the actual value is USD 348 K.EPS: As of FY2025 Q3, the actual value is USD -0.61.EBIT: As of FY2025 Q3, the actual value is USD -61.86 M.<h3>Segment Revenue</h3><ul><li>Total Revenue: $22.5 million for the nine months ended September 30, 2025, compared to $32.8 million for the same period in 2024, a decrease of $10.3 million or 31%.</li></ul><h3>Operational Metrics</h3><ul><li>Operating Loss: $159.7 million for the nine months ended September 30, 2025, compared to $133.1 million for the same period in 2024, an increase of $26.6 million.</li><li>Net Loss: $128.9 million for the nine months ended September 30, 2025, compared to $149.4 million for the same period in 2024, a decrease of $20.5 million.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $106.9 million for the nine months ended September 30, 2025, compared to $121.1 million for the same period in 2024, a decrease of $14.2 million.</li><li>Net Cash Used in Investing Activities: $153.8 million for the nine months ended September 30, 2025, compared to $0.7 million for the same period in 2024, primarily due to investments in marketable securities.</li><li>Net Cash Provided by Financing Activities: $15.8 million for the nine months ended September 30, 2025, compared to $202.9 million for the same period in 2024, a decrease of $187.1 million.</li></ul><h3>Unique Metrics</h3><ul><li>Interest Income: $21.1 million for the nine months ended September 30, 2025, compared to $12.4 million for the same period in 2024, an increase of $8.7 million or 70%.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focused on the development and commercialization of obicetrapib, a CETP inhibitor, for LDL-C lowering therapy. The company plans to commercialize obicetrapib in the United States and is considering additional partners for other jurisdictions.</li><li>Non-Core Business: The company has partnered with Menarini for the commercialization of obicetrapib in Europe and is exploring potential acquisitions or licenses of new product candidates.</li><li>Priority: The company is conducting a Phase 3 cardiovascular outcomes trial, PREVAIL, which is expected to conclude by the end of 2026, subject to the occurrence of the target number of MACE events.</li></ul>

Newamsterdam Pharma - CW27 | 10-Q: FY2025 Q3 Revenue: USD 348 K